Barcelona, July 30, 2020.- VHIO-born spin-off Peptomyc S.L. –co-founded in 2014 by VHIO’s Laura Soucek, also CEO of the enterprise…
Designation elevates site as a Syneos Health partner for best clinical research practices Barcelona, July 30, 2020.- The Vall d’Hebron…
Barcelona, July 27, 2020.– Primary central nervous system (CNS) lymphoma is a rare, highly aggressive tumor type whose biological characteristics…
The results of the NALA study –a multicenter, phase III, registration study in patients with HER2+ breast cancer who had…
DIAMAV, VHIO’s molecular diagnosis program, guides clinicians in the selection of cost-effective anti-cancer treatments and facilitates clinical-molecular research. The program…
The increasing number and complexity of biomarkers that guide the selection of new therapies against cancer fragments knowledge on the…
Avapritinib is the first effective drug in patients with advanced gastrointestinal stromal tumors (GISTs) carrying the PDGFRA D842V mutation. This…
Barcelona, June 29, 2020.- The National Research Award, with a 30-year history, is one of the most prestigious awards bestowed…
Persistency of Fusobacterium nucleatum, an intestinal bacterium, in rectal tumors after chemotherapy is associated with high risk of relapse in…
In the past, no therapeutic alternatives were available for patients who had exhausted up to three lines of treatment with…
Barcelona, June 02, 2020.- A VHIO researcher has won funding from the CRIS Foundation for her project to improve cancer…
Vall d’Hebron has taken part in a clinical trial that could change clinical practice in patients with this subtype of…
